Ionis Pharmaceuticals (IONS) Total Debt (2009 - 2026)

Ionis Pharmaceuticals' Total Debt history runs 18 years deep, the most recent figure standing at $432.5 million for Q1 2026.

• On a quarterly basis, Total Debt changed N/A year-over-year to $432.5 million in Q1 2026; TTM through Mar 2026 was $432.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $460.1 million, up 786.04% from the prior year.
• Total Debt slipped to $432.5 million in Q1 2026 per IONS's latest filing, from $460.1 million in the prior quarter.
• Across five years, Total Debt topped out at $630.9 million in Q3 2025 and bottomed at $8.8 million in Q1 2023.
• The 5-year median for Total Debt is $44.4 million (2024), against an average of $181.4 million.
• Across the five-year window, Total Debt tumbled 75.44% in 2022 and jumped 1318.83% in 2025, its largest moves.
• Year by year, Total Debt stood at $16.0 million in 2022, then soared by 439.46% to $86.2 million in 2023, then sank by 39.74% to $51.9 million in 2024, then jumped by 786.04% to $460.1 million in 2025, then declined by 5.99% to $432.5 million in 2026.
• Per Business Quant, the three latest IONS Total Debt figures stand at $432.5 million (Q1 2026), $460.1 million (Q4 2025), and $630.9 million (Q3 2025).